Endomorphin-1 attenuates Aβ42 induced impairment of novel object and object location recognition tasks in mice

Brain Research

Volumn 1629, Issue , 2015, Pages 210-220

  Zhang, Rui San ^a   Xu, Hong Jiao ^a   Jiang, Jin Hong ^a   Han, Ren Wen ^a   Chang, Min ^a   Peng, Ya Li ^a   Wang, Yuan ^a   Wang, Rui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Alzheimers disease; Amyloid ; Endomorphin 1; Recognition memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ENDOMORPHIN 1; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OLIGOPEPTIDE; PEPTIDE FRAGMENT;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MEMORY DISORDERS; MOUSE; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RECOGNITION;

AMYLOID BETA-PEPTIDES; ANALGESICS, OPIOID; ANIMALS; INFUSIONS, INTRAVENTRICULAR; MALE; MEMORY DISORDERS; MICE; NALOXONE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, OPIOID, MU; RECOGNITION (PSYCHOLOGY);

EID: 84955467752     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.10.028     Document Type: Article

References (49)

1. C. Adessi, M.J. Frossard, C. Boissard, S. Fraga, S. Bieler, T. Ruckle, F. Vilbois, S.M. Robinson, M. Mutter, W.A. Banks, and C. Soto Pharmacological profiles of peptide drug candidates for the treatment of Alzheimers disease J. Biol. Chem. 278 2003 13905 13911
2. C.F. Albright, R.C. Dockens, J.E. Meredith Jr., R.E. Olson, R. Slemmon, K.A. Lentz, J.S. Wang, R.R. Denton, G. Pilcher, P.W. Rhyne, J.J. Raybon, D.M. Barten, C. Burton, J.H. Toyn, S. Sankaranarayanan, C. Polson, V. Guss, R. White, F. Simutis, T. Sanderson, K.W. Gillman, J.E. Starrett Jr., J. Bronson, O. Sverdlov, S.P. Huang, L. Castaneda, H. Feldman, V. Coric, R. Zaczek, J.E. Macor, J. Houston, R.M. Berman, and G. Tong Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat J. Pharmacol. Exp. Ther. 344 2013 686 695
3. F. Belluti, A. Rampa, S. Gobbi, and A. Bisi Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimers disease: a patent review (2010-2012) Expert Opin. Ther. Pat. 23 2013 581 596
4. M.A. Chacon, M.I. Barria, C. Soto, and N.C. Inestrosa Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits Mol. Psychiatry 9 2004 953 961
5. J. Cui, Y. Wang, Q. Dong, S. Wu, X. Xiao, J. Hu, Z. Chai, and Y. Zhang Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70 J. Neurosci. 31 2011 16227 16240
6. A.T. Dao, M.A. Zagaar, A.T. Levine, S. Salim, J.L. Eriksen, and K.A. Alkadhi Treadmill exercise prevents learning and memory impairment in Alzheimers disease-like pathology Curr. Alzheimer Res. 10 2013 507 515
7. A.T. Dao, M.A. Zagaar, S. Salim, J.L. Eriksen, and K.A. Alkadhi Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimers disease Int. J. Neuropsychopharmacol. 17 2014 593 602
8. de T.L. oledo-Morrell, T.R. Stoub, and C. Wang Hippocampal atrophy and disconnection in incipient and mild Alzheimers disease Prog. Brain Res. 163 2007 741 753
9. M.A. Findeis Peptide inhibitors of beta amyloid aggregation Curr. Topics Med. Chem. 2 2002 417 423
10. V.H. Finder, and R. Glockshuber Amyloid-beta aggregation Neuro-degener. Dis. 4 2007 13 27
11. A. Frydman-Marom, M. Rechter, I. Shefler, Y. Bram, D.E. Shalev, and E. Gazit Cognitive-performance recovery of Alzheimers disease model mice by modulation of early soluble amyloidal assemblies Angew. Chem. Int. Ed. 48 2009 1981 1986
12. A. Frydman-Marom, M. Convertino, R. Pellarin, A. Lampel, R. Shaltiel-Karyo, D. Segal, A. Caflisch, D.E. Shalev, and E. Gazit Structural basis for inhibiting beta-amyloid oligomerization by a non-coded beta-breaker-substituted endomorphin analogue ACS Chem. Biol. 6 2011 1265 1276
13. E. Gazit The role of prefibrillar assemblies in the pathogenesis of amyloid diseases Drugs Future 29 2004 613 619
14. D. Giuliani, A. Ottani, D. Zaffe, M. Galantucci, F. Strinati, R. Lodi, and S. Guarini Hydrogen sulfide slows down progression of experimental Alzheimers disease by targeting multiple pathophysiological mechanisms Neurobiol. Learn. Mem. 104 2013 82 91
15. R.W. Han, M. Chang, Y.L. Peng, L.Y. Qiao, X.Q. Yin, W. Li, and R. Wang Central Neuropeptide S inhibits distal colonic transit through activation of central Neuropeptide S receptor in mice Peptides 30 2009 1313 1317
16. R.W. Han, R.S. Zhang, M. Chang, Y.L. Peng, P. Wang, S.Q. Hu, C.L. Choi, M. Yin, R. Wang, and Y.F. Han Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins Brain Res. 1470 2012 59 68
17. R.W. Han, R.S. Zhang, H.J. Xu, M. Chang, Y.L. Peng, and R. Wang Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Abeta(1-42) in mice novel object and object location recognition tasks Neuropharmacology 70 2013 261 267
18. R.W. Han, H.J. Xu, R.S. Zhang, P. Wang, M. Chang, Y.L. Peng, K.Y. Deng, and R. Wang Neuropeptide S interacts with the basolateral amygdala noradrenergic system in facilitating object recognition memory consolidation Neurobiol. Learn. Mem. 107 2014 32 36
19. R. Horn, B. Ostertun, M. Fric, L. Solymosi, A. Steudel, and H.J. Moller Atrophy of hippocampus in patients with Alzheimers disease and other diseases with memory impairment Dementia 7 1996 182 186
20. T. Iuvone, D. De Filippis, G. Esposito, A. DAmico, and A.A. Izzo The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity J. Pharmacol. Exp. Ther. 317 2006 1143 1149
21. J. Kang, H.G. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K.H. Grzeschik, G. Multhaup, K. Beyreuther, and B. Muller-Hill The precursor of Alzheimers disease amyloid A4 protein resembles a cell-surface receptor Nature 325 1987 733 736
22. W. Kim, Y. Kim, J. Min, D.J. Kim, Y.T. Chang, and M.H. Hecht A high-throughput screen for compounds that inhibit aggregation of the Alzheimers peptide Acs Chem. Biol. 1 2006 461 469
23. Y. Lu, D. Riddell, E. Hajos-Korcsok, K. Bales, K.M. Wood, C.E. Nolan, A.E. Robshaw, L. Zhang, L. Leung, S.L. Becker, E. Tseng, J. Barricklow, E.H. Miller, S. Osgood, B.T. ONeill, M.A. Brodney, D.S. Johnson, and M. Pettersson Cerebrospinal fluid amyloid-beta (Abeta) as an effect biomarker for brain Abeta lowering verified by quantitative preclinical analyses J. Pharmacol. Exp. Ther. 342 2012 366 375
24. A. Maruszak, and S. Thuret Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimers disease diagnosis Front. Cell. Neurosci. 8 2014 95
25. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, and K. Beyreuther Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. USA 82 1985 4245 4249
26. A. Nitta, A. Itoh, T. Hasegawa, and T. Nabeshima beta-Amyloid protein-induced Alzheimers disease animal model Neurosci. Lett. 170 1994 63 66
27. N. Okamura, C. Garau, D.M. Duangdao, S.D. Clark, K. Jungling, H.C. Pape, and R.K. Reinscheid Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain Neuropsychopharmacology 36 2011 744 752
28. G. Paxinos, K.B.J. Franklin, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates 2001 Academic Press San Diego
29. D.L. Price, and S.S. Sisodia Mutant genes in familial Alzheimers disease and transgenic models Annu. Rev. Neurosci. 21 1998 479 505
30. D.J. Selkoe Normal and abnormal biology of the beta-amyloid precursor protein Annu. Rev. Neurosci. 17 1994 489 517
31. D.J. Selkoe Alzheimers disease: a central role for amyloid J. Neuropathol. Exp. Neurol. 53 1994 438 447
32. M.K. Shin, H.G. Kim, S.H. Baek, W.R. Jung, D.I. Park, J.S. Park, D.G. Jo, and K.L. Kim Neuropep-1 ameliorates learning and memory deficits in an Alzheimers disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques Neurobiolo. Aging 35 2014 990 1001
33. H.S. Soininen, and P. Scheltens Early diagnostic indices for the prevention of Alzheimers disease Ann. Med. 30 1998 553 559
34. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimers therapy Nat. Med. 4 1998 822 826
35. N. Suzuki, T.T. Cheung, X.D. Cai, A. Odaka, L. Otvos, C. Eckman, T.E. Golde, and S.G. Younkin An increased percentage of long amyloid-beta protein secreted by familial amyloid-beta protein-precursor (Beta-App717) mutants Science 264 1994 1336 1340
36. V. Szegedi, G. Juhasz, E. Rozsa, G. Juhasz-Vedres, Z. Datki, L. Fulop, Z. Bozso, A. Lakatos, I. Laczko, T. Farkas, Z. Kis, G. Toth, K. Soos, M. Zarandi, D. Budai, J. Toldi, and B. Penke Endomorphin-2, an endogenous tetrapeptide, protects against Abeta1-42 in vitro and in vivo FASEB J. 20 2006 1191 1193
37. M. Ukai, Y. Watanabe, and T. Kameyama Effects of endomorphins-1 and -2, endogenous mu-opioid receptor agonists, on spontaneous alternation performance in mice Eur. J. Pharmacol. 395 2000 211 215
38. M. Ukai, T. Katoh, and T. Mamiya Endomorphin-1 improves scopolamine-induced impairment of short-term memory via mu1-opioid receptor in mice Neuroreport 12 2001 3723 3727
39. M. Ukai, Y. Watanabe, and T. Kameyama Endomorphins 1 and 2, endogenous mu-opioid receptor agonists, impair passive avoidance learning in mice Eur. J. Pharmacol. 421 2001 115 119
40. J.W. Um, A.C. Kaufman, M. Kostylev, J.K. Heiss, M. Stagi, H. Takahashi, M.E. Kerrisk, A. Vortmeyer, T. Wisniewski, A.J. Koleske, E.C. Gunther, H.B. Nygaard, and S.M. Strittmatter Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer A beta oligomer bound to cellular prion protein Neuron 79 887 2013 80, 531-531
41. K.L. Viola, P.T. Velasco, and W.L. Klein Why Alzheimers is a disease of memory: the attack on synapses by a beta oligomers (ADDLs) J. Nutr. Health Aging 12 2008 51S 57SS
42. C.L. Wang, Y. Zhou, C. Guo, Y. Zhang, and R. Wang In vivo characterization of intestinal effects of endomorphin-1 and endomorphin-2 in type 1 diabetic mice Eur. J. Pharmacol. 698 2013 499 504
43. Y. Wang, Y. Xing, X. Liu, H. Ji, M. Kai, Z. Chen, J. Yu, D. Zhao, H. Ren, and R. Wang A new class of highly potent and selective endomorphin-1 analogues containing alpha-methylene-beta-aminopropanoic acids (map) J. Med. Chem. 55 2012 6224 6236
44. M. Wirth, S. Villeneuve, C.M. Haase, C.M. Madison, H. Oh, S.M. Landau, G.D. Rabinovici, and W.J. Jagust Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people JAMA Neurol. 70 2013 1512 1519
45. P.C. Wong, H. Cai, D.R. Borchelt, and D.L. Price Genetically engineered mouse models of neurodegenerative diseases Nat. Neurosci. 5 2002 633 639
46. N. Wu, X. Rao, Y. Gao, J. Wang, and F. Xu Amyloid-beta deposition and olfactory dysfunction in an Alzheimers disease model J. Alzheimers Dis. 37 2013 699 712
47. B.A. Yankner Mechanisms of neuronal degeneration in Alzheimers disease Neuron 16 1996 921 932
48. J.E. Zadina, L. Hackler, L.J. Ge, and A.J. Kastin A potent and selective endogenous agonist for the mu-opiate receptor Nature 386 1997 499 502
49. J.E. Zadina, S. Martin-Schild, A.A. Gerall, A.J. Kastin, L. Hackler, L.J. Ge, and X. Zhang Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density Ann. N. Y. Acad. Sci. 897 1999 136 144